Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: A tissue microarray study using immunohistochemistry and fluorescent in situ hybridization

International Journal of Gynecological Pathology

Volumn 30, Issue 4, 2011, Pages 372-379

  Lin, Chih Kuang ^a   Lin, Wea Lung ^b   Chen, Fong Lin ^a   Lee, Ming Yung ^c   Kuo, Jang Fang ^b   Ruan, Alexandra ^e   Tyan, Yeu Sheng ^f   Chiang, Hung ^d   Chou, Ming Chih ^a   Han, Chih Ping ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c PROVIDENCE UNIVERSITY   (Taiwan)

^d Taipei Institute Pathology   (Taiwan)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NONE

Author keywords

Epithelial ovarian cancer; Her2 gene; HER2 protein; Polysomy 17

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; CHROMOSOME ABERRATION; EPITHELIAL OVARY CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; POLYSOMY 17; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANEUPLOIDY; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MICROARRAY ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958813689     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31820c9ff3     Document Type: Article

References (24)

1. Goff BA, Muntz HG, Greer BE, et al. Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol 1998;92:88-3.
2. Rubin SC, Finstad CL, Federici MG, et al. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;3:1456-59. (Pubitemid 24072553)
3. Rubin SC, Finstad CL, Wong GY, et al. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993;168:162-9. (Pubitemid 23047634)
4. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91. (Pubitemid 20225635)
5. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88. (Pubitemid 32458162)
6. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-33.
7. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 2009;17:1-7.
8. Odicino FE, Bignotti E, Rossi E, et al. HER-2/neu over-expression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer 2008;18:14-21.
9. García-Velasco A, Mendiola C, Sánchez-Muñoz A, et al. Prognostic value of hormonal receptors, p53, ki67 and HER2/ neu expression in epithelial ovarian carcinoma. Clin Transl Oncol 2008;10:367-71.
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
11. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006;19:97-105. (Pubitemid 43250984)
12. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-24. (Pubitemid 40170640)
13. Köbel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222:191-8.
14. Kritpracha K, Hanprasertpong J, Chandeying V, et al. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res 2005;31:268-76. (Pubitemid 40943740)
15. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, et al. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 2004;53:166-75. (Pubitemid 38328039)
16. Downs-Kelly E, Yoder BJ, Stoler M, et al. The impact of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast. Am J Surg Pathol 2005;29:1221-27.
17. Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 2003;5:155-9. (Pubitemid 36974726)
18. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 2004;121:70-7. (Pubitemid 38090156)
19. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol 2009;27:2962-69.
20. Hawes D, Liu PY, Muggia FM, et al. Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecol Oncol 2002;87:17-23. (Pubitemid 36027096)
21. Nakayama K, Takebayashi Y, Nakayama S, et al. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 2003;192:227-35. (Pubitemid 36369277)
22. Antilla M, Kosma VM, Ji H, et al. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 1998;16:2591-600. (Pubitemid 28363021)
23. Santin AD, Bellone S, Gokden M, et al. Overexpression of Her-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271-79. (Pubitemid 34517668)
24. Jones LA, Edwards CL, Freedman RS, et al. Estrogen and progesterone receptor titters in primary epithelial ovarian carcinomas. Int J Cancer 1983;32:567-71. (Pubitemid 14247899)